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Abstract
Background: During Chikungunya virus (CHIKV) epidemic in Nagpur, India, we identified some suspected
Chikungunya patients with neurological complications. Early and cost-effective diagnosis of these patients remains
problematic despite many new advanced diagnostic methods. A reliable diagnostic test, which could be
performed in any standard pathology laboratory, would help to obtain definitive early diagnosis of CHIKV patients
with neurological complications. In our laboratory, in-house ELISA protocol for viral antigen, immunoglobulin M
(IgM) and IgG detection has been developed and assessed for the diagnosis of CHIKV patients with neurological
complications.
Method: Cerebrospinal fluid samples of forty-six patients who developed neurological symptoms within two
months of CHIKV infections along with control subjects were included in the study and were analyzed for the
presence of antigens and of IgM and IgG using an ELISA protocol.
Results: The ELISA method for antigen detection yielded 80% sensitivity and 87% specificity for the diagnosis of
CHIKV patients with neurological complications. The sensitivity for detection of IgM 48% or IgG 63% was
significantly lower than the antigen assay (80%).
Conclusion: The detection of viral antigen in CSF of CHIKV patients with neurological complications by ELISA
method gave a more reliable diagnosis than antibodies detection that can be used to develop an
immunodiagnostic assay with increased sensitivity and specificity.
Background
Chikungunya virus (CHIKV) is an insect-borne virus, of
the genus, Alphavirus, that is transmitted to humans by
virus-carrying Aedes mosquitoes [1]. There have been
recent outbreaks of CHIKV associated with severe mor-
bidity. CHIKV causes an illness with symptoms similar
to dengue fever and manifests itself with an acute febrile
phase of the illness which lasts only 2-5 days, followed
by a prolonged arthralgic disease that affects the joints
of the extremities [2]. The pain associated with CHIKV
infection of the joints persists for weeks or months and
in some cases even for years.
In 2006, an outbreak was recorded in different areas of
Maharashtra state. Over 2000 cases of Chikungunya fever
have been reported from Malegaon town in Nasik dis-
trict, Maharashtra state, India between February-March
2006 [3]. In May 2006, a big outbreak in Nagpur district
of Maharashtra was also reported. In Nagpur city alone,
as per communication of District Health Officer, in Gov-
ernment dispensaries 50 to 100 cases of Chikungunya
were seen everyday. Patients treated by private medical
practitioners were not included in these numbers [4].
Some deaths have been reported, but these have been
attributed mainly to inappropriate management. The
major causes of morbidity included severe dehydration,
electrolyte imbalance, and loss of glycemic control.
During the epidemic, in our institute we have identified
several suspected CHIKV patients associated with
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primary referral centre for neurological illnesses and serves
as tertiary referral centre for patients not only from
Vidarbha (Part of Maharashtra, India), but also from
adjoining states like Madhya Pradesh, Chhattisgarh and
Andhra Pradesh. To our knowledge, only a few CHIKV-
associated neurological manifestations have been reported
previously in the Indian subcontinent. However recently,
some cases of CHIKV meningoencephalitis and myelopa-
thy were reported from the Reunion Islands [6,7].
Monitoring the clinical features of CHIKV infection is
an important component of assessing the disease pro-
cess in humans so as to determine which organ system
including the nervous system is affected. Laboratory
tests are necessary to confirm the diagnosis of CHIKV.
The immunoglobulin M (IgM) capture ELISA method,
which provides evidence of CHIKV infection, is widely
used to lend support to clinical findings in the assess-
ment of patients with suspected CHIKV [8]. However,
the sensitivity of IgM capture ELISA is low in the
majority of patients in the acute stage (days 1-5); there-
fore, a negative IgM capture ELISA does not rule out
the diagnosis. The specificity of IgM capture ELISA is
also limited because of cross-reactivity with dengue or
other infections. IgG cannot be detected in CHIKV
patients in the acute stage.
A rapid antigen detection test using ELISA for CHIKV
infection may be a more accurate diagnostic method for
CHIKV patients with associated with neurological com-
plications. In our laboratory, we have developed an
ELISA based viral antigen detection assay for the diag-
nosis of CHIKV infection. The test was evaluated in
serum samples from CHIKV patients with a sensitivity
and specificity of 85% and 89% (9). In the present study,
cerebrospinal fluid (CSF) specimens from CHIKV
patients associated with neurological complications been
examined by a sensitive and specific indirect ELISA pro-
tocol developed in our laboratory. The purpose of the
study was to evaluate the sensitivity and specificity of
rapid antigen ELISA compared to IgG and IgM tests
and also to determine their efficacy in absence of mole-
cular techniques.
Materials and methods
Study subjects
Three hundred patients of clinically-suspected CHIKV
infections were enrolled for the study from July-December
2006 at the Central India Institute of Medical Sciences
(CIIMS), Nagpur, India. All patients had typical clinical
features of CHIKV infection fever, headache, body ache,
myalgia, and joint pains with or without swelling and with-
out hemorrhagic rash. Forty-six patients who developed
neurological symptoms were hospitalized. Patients show-
ing any neurological symptoms (encephalitis, myelopathy,
neuropathy, myeloneuropathy or myopathy) along with
the typical Chikungunya infection symptoms i.e. joint pain
with or without swelling, rashes and fever were considered
for the study. Any patients presenting pain clearly related
to other etiologies such as rheumatologic, muscular,
migraines, diabetes, psychiatric illness etc were excluded
since they could confound the analysis. Patients with
entrapment neuropathy were also excluded from the
study. All had detailed neurological evaluation and blood
investigations. Depending on the neurological syndrome,
patients were further investigated using CSF analysis, elec-
trodiagnostic tests, electroencephalography (EEG), evoked
potential studies, and neuroimaging, computerized
tomograpy (CT) and/or magnetic resonance imaging
(MRI). Molecular tests reverse transcriptase polymerase
chain reaction, [RT-PCR], real-time PCR and virus isola-
tion were done in all the patients included in the present
study, first in serum samples and then in CSF.
Neurological infection of CHIKV was confirmed if
reverse transcription polymerase chain reaction (RT-
PCR) and/or real time PCR or virus isolation in CSF
samples were positive and were included in the con-
firmed Neuro-CHIKV group. When all these tests were
negative, the patients were diagnosed by above men-
tioned clinical symptoms and formed the suspected
neuro-CHIKV group. Patients were given supportive
care as per the clinical syndrome and the course of the
illness. Some received a course of methyl prednisolone
1g daily for 3-5 days. Fifteen patients, who had no clini-
cal features of Chikungunya and had no evidence of
CNS or extra-CNS infections, and were negative for
PCR or virus isolation, were grouped in the Non-
CHIKV and analyzed as a control group. The median
age of the study subjects was 45 years (range, 5-85
years). The Institutional Ethics Committee of the
CIIMS, Nagpur, India approved the study.
CSF sampling and handling
CSF was collected by standard lumbar puncture.
Approximately 5-10 ml CSF was obtained, part of it was
used for routine biochemical and pathological analysis
including gram staining, India ink staining and AFB
staining and culturing and the remaining CSF was used
for the ELISA study. CSF samples were collected from
all study groups for which patients’ written consent was
obtained. All the samples were stored at 4°C until
further analysis.
CHIKV antigen and antibodies
The CHIKV antigen used in the ELISA test was pre-
pared using an Indian strain of Chikungunya virus
CHIKV ISW HYD06 (Gene Bank accession number
876190). Pooled sera from CHIKV patients was col-
lected, and IgG (antibodies) was purified by protein G
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Bangalore Genei, India) according to the manufacturer’s
instructions and used at a dilution of 1:10,000.
ELISA (CHIKV antigen detection)
CSF samples (100 μl ,d i l u t e d1 : 5 )f r o mC H I K Vp a t i e n t s
who have neurological complications were added to the
microtiter wells, incubated for 60 min and then blocked
with 0.5% BSA in PBS-T (phosphate buffered saline -
tween-20) for 60 min. After the samples were washed
with PBS-T, anti-CHIKV IgG was added (1:10,000) and
the plates were incubated at 37°C for 60 min. After
incubation, wells were washed and goat-anti-human
IgG-HRP (Horseradish peroxidase) secondary antibody
(1:10,000 dilution) was added. Then samples were incu-
bated for 60 min at 37°C. After another wash with PBS,
100 μlo fT M B / H 2O2 (tetramethylbenzidine - hydrogen
peroxide) substrate solution was added to the wells,
which were incubated at room temperature for approxi-
mately 10 min. The reaction was then terminated with
100 μlo f2 . 5NH 2SO4. The absorbance of each well
was read at 450 nm.
ELISA (CHIKV antibodies detection)
The immunoglobulin (IgM) and IgG antibodies to
CHIKV were detected in CSF by ELISA. The ELISA pro-
tocol detected IgG and IgM antibodies directed against
CHIKV antigens. The viral antigens (1:2 dilution) in PBS-
T were coated onto the microtitre wells. After 90 min of
incubation at room temperature, the wells were washed
with PBS-T, and after blocking with 0.5% BSA in PBS-T
for 60 min, CSF samples (1:5 dilution) were added to the
wells and incubated for 60 min. After the incubation,
100 μl of goat anti-human IgG or IgM conjugated with
horseradish peroxidase was added. After another washing
with PBS, 100 μlo fT M B / H 2O2 substrate solution was
added to the wells, which were incubated at room tem-
perature for approximately 10 min. The reaction was ter-
minated with 100 μl of 2.5 N H2SO4. The absorbance of
each well was read at 450 nm.
Statistical analysis
The results were expressed as the mean ± standard
deviation (SD) together with the range. Comparisons of
the proportions of positive results were made between
the different tests and subgroups by using the Kruskal-
Wallis test (nonparametric analysis of variance) with
Dunnett’s post test. A P value of less than 0.05 was con-
sidered significant. The sensitivity (true-positive rate) for
the test was calculated as [the number of samples in the
CHIKV-infected group with an absorbance of greater
than or equal to the (mean + SD) of the absorbance for
the healthy group divided by the total number of
samples for the CHIKV-infected group] X100. The spe-
cificity (true-negative rate) for the test was calculated as
[the number of samples in theC H I K V - i n f e c t e dg r o u p
with an absorbance less than the (mean + SD) of the
absorbance for the healthy group divided by the total
number of samples for the healthy group] × 100.
Results
Three hundred patients of clinically suspected CHIKV
infections were seen during the period of June 2006 to
December 2006 and followed up for any neurological com-
plications until April 2007. Forty six out of 300 patients
enrolled for the study developed neurological complica-
tions. Among them, 39 were males and 7 were females.
With one exception, all patients developing neurological
complications were over 20 years of age. The majority of
the patients developed neurological complications within
20 days of onset of CHIKV infection. Thirty-three out of
46 patients were given corticosteroid treatment and
remaining kept on supportive treatment. All the patients
improved irrespective of type of treatment except 2
patients; one from the encephalitic group and another
from myeloneuropathy group expired.
CHIKV antigen assay
The CSF positivities for CHIKV antigen in cases of con-
firmed neuro-CHIKV and suspected patients were 100%
(9/9) and 76% (28/37) respectively, while the positivity
for patients in the Non-CHIKV group was 13% (02/15)
(Table 1). The mean absorbance value of CHIKV anti-
gen in CSF from the CHIKV and non CHIKV groups as
determined by the ELISA method is shown in Figure
1A. The mean absorbance value of CHIKV antigen in
the confirmed neuro-CHIKV patients was 0.84 ± 0.19
and for suspected Chikungunya patients was 0.64 ± 0.19
which were significantly higher than the non CHIKV
group (0.36 ± 0.08; P < 0.001). There was a significant
difference in the mean CHIKV antigen activity between
the confirmed neuro-CHIKV patients (0.84 ± 0.23) and
the suspected-CHIKV patients (0.59 ± 0.14; P < 0.05).
IgM assay
Table 2 shows the positivity for IgM assay in cases of
confirmed neuro-CHIKV patients, suspected CHIKV
patients and non CHIKV group. The CSF positivity for
CHIKV IgM in confirmed CHIKV patients was 89%
(8/9) and 38% (14/37) for the suspected CHIKV patients
while the positivity for patients in the non CHIKV
group was 27% (04/15). The mean IgM level of 0.85 ±
0.16 in the confirmed neuro-CHIKV group and 0.68 ±
0.16 in the suspected neuro-CHIKV group were signifi-
cantly higher than the non CHIKV group 0.30 ± 0.07,
P < 0.01 and 0.05 respectively (Figure 1B).
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IgG detection in confirmed and suspected neuro-CHIKV
patients were 56% (5/9) and 65% (24/37) respectively as
given in Table 3. The IgG positivity for patients in the non
CHIKV group was quite high i.e. 53% (8/15). Figure 1C
shows the mean absorbance value of IgG in confirmed
n e u r o - C H I K Vg r o u pw a s0 . 5 6±0 . 0 8a n di ns u s p e c t e d
neuro-CHIKV was 0.43 ± 0.08, both were significantly
higher than the non-CHIKV group 0.24 ± 0.08, P <0 . 0 1
and 0.05, respectively.
Overall, our study suggests that the antigen detection
in both confirmed as well as suspected neuro-CHIKV
groups was positive in the majority of patients (80%),
while this was not the case for detection of IgM (48%)
or IgG (63%).
Discussion
The first report on CHIKV infection with neurological
complication was reported in the 1960 s. There were
some reports which suggest that this infection was found
to be associated with meningoencephalitis, myelitis, and
choroiditis [9,10]. In the recent epidemic various neuro-
logical complications have been reported which include
meningo-encephalitis, meningo-encephalo-myeloradicu-
litis, myeloradiculitis, myelitis, myeloneuropathy,
Guillain-Barre’ syndrome, external opthalmoplegia, facial
palsy, sensorineural deafness, and optic neuritis. As
reported by others and from our laboratory encephalitis
appears to represent the most common clinical manifes-
tation and occurs either simultaneously or within few
days of onset of systemic symptoms, during the period of
viremia [5,9].
Molecular tests have also been developed but these
methods require sophisticated technology and well-
trained personnel. In addition, viral RNA is not usually
detected in the serum after defervescence [11]. In addi-
tion to that, various immunoassays for detecting antibo-
dies (IgG and IgM) in serum samples have been used
[12-14]. However, despite extensive work on the
CHIKV, diagnosis the sensitivity and specificity of these
methods are limited. Our goal was to determine whether
antigen detection instead of antibody detection improves
Table 1 Demonstration of CHIKV antigen in CSF of Neuro-CHIKV and Non-CHIKV group by ELISA method
Study Subjects Positivity for CHIKV Antigen (%) Negativity for CHIKV Antigen (%)
Neuro-CHIKV patients (n = 46) 37 (80%) 9 (20%)
Confirmed (n = 9) 9 (100%) 0
Encephalitis (n = 4) 4 (100%) 0
Myelopathy (n = 2) 2 (100%) 0
Myeloneuropathy (n = 1) 1 (100%) 0
Peripheral Neuropathy (n = 1) 1 (100%) 0
Myopathy (n = 1) 1 (100%) 0
Suspected (n = 37) 28 (76%) 9 (24%)
Encephlitis (n = 20) 16 (80%) 4 (20%)
Myelopathy (n = 5) 5 (100%) 0
Myeloneuropathy (n = 6) 4 (67%) 2 (33%)
Peripheral Neuropathy (n = 6) 3 (50%) 3 (50%)
Non-CHIKV patients (n = 15) 2 (13%) 13 (87%)
Figure 1 Mean absorbance values of ELISA assays for a) CHIKV viral antigen, b) CHIKV IgM, c) CHIKV IgG in CSF from patients with
confirmed (n = 9) and suspected CHIKV (n = 37) with neurological complications and patients from non-CHIKV group (n = 15). Data
are means +/- SD. * P < 0.05, ** P < 0.01 relative to control non-CHIKV subjects.
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tion in routine medical practice. ELISA-based CHIKV
antigen detection which was developed in our laboratory
was evaluated in the CSF collected from suspected cases
of CHIKV infection with neurological complications
along with a control group.
The data demonstrate that the positivities for CHIKV
antigen in CSF from cases of confirmed and clinically-
diagnosed CHIKV patients with neurological complica-
tions were better than the IgM and IgG detection
method. To the best of our knowledge, this is the first
ELISA-based antigen detection method reported and the
first study that reports a comparison between antigen
and antibody detection in the same CSF samples. Hun-
dekar et al have developed a monoclonal antibody-based
antigen capture ELISA to detect Chikungunya virus
antigen in mosquitoes, but not in body fluids [15].
There are many studies on IgG and IgM analysis per-
formed in serum samples of Chikungunya patients. Sur-
yawanshi et al have done IgM analysis in 166 serum
samples selected from suspected and confirmed cases of
Chikungunya patients. Out of that 87 (52.4%) were posi-
tive for the developed test [16].
The antigen detection assay which we have developed
in our laboratory measures the viral protein in the CSF,
which is detectable earlier than IgG and IgM during
acute infection. This early detection is due to the initial
burst of virus replication and is associated with high
levels of viremia, and during which time the individual
is highly infectious.
Conclusions
The diagnostic sensitivity of CHIKV antigen detection
using an ELISA-based system is higher than that of con-
ventional IgM and IgG tests and helpful in the detection
of antigen throughout the infection, even in the earlier
stages of infection. The ELISA method used in this
study is sensitive, specific, rapid, and cost-effective, and
it can be adopted by any laboratory with an ELISA
reader and an incubator. It may thus be useful in
laboratories with limited resources, especially in under-
developed and developing countries.
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Table 2 Demonstration of CHIKV IgM in CSF of Neuro-
CHIKV and Non-CHIKV group by ELISA method
Study Subjects Positivity for
IgM (%)
Negativity for
IgM (%)
Neuro-CHIKV patients (n = 46) 22 (48%) 24 (52%)
Confirmed (n = 9) 8 (89%) 1 (11%)
Encephalitis (n = 4) 3 (75%) 1 (25%)
Myelopathy (n = 2) 2 (100%) 0
Myeloneuropathy (n = 1) 1 (100%) 0
Peripheral Neuropathy (n = 1) 1 (100%) 0
Myopathy (n = 1) 1 (100%) 0
Suspected (n = 37) 14 (38%) 23 (62%)
Encephlitis (n = 20) 5(25%) 15 (75%)
Myelopathy (n = 5) 3 (60%) 2 (40%)
Myeloneuropathy (n = 6) 4 (67%) 2 (33%)
Peripheral Neuropathy (n = 6) 2 (33%) 4 (67%)
Non-CHIKV patients (n = 15) 4 (27%) 11 (73%)
Table 3 Demonstration of CHIKV IgG in CSF of Neuro-
CHIKV and Non-CHIKV group by ELISA method
Study Subjects Positivity for
IgG (%)
Negativity for
IgG (%)
Neuro-CHIKV patients (n = 46) 29 (63%) 17 (37%)
Confirmed (n = 9) 5 (56%) 4 (44%)
Encephalitis (n = 4) 1 (25%) 3 (75%)
Myelopathy (n = 2) 1 (50%) 1 (50%)
Myeloneuropathy (n = 1) 1 (100%) 0
Peripheral Neuropathy (n = 1) 1 (100%) 0
Myopathy (n = 1) 1 (100%) 0
Suspected (n = 37) 24 (65%) 13 (35%)
Encephalitis (n = 20) 15 (75%) 5 (25%)
Myelopathy (n = 5) 4 (80%) 1 (20%)
Myeloneuropathy (n = 6) 1 (17%) 5 (83%)
Peripheral Neuropathy (n = 6) 4 (67%) 2 (33%)
Non-CHIKV patients (n = 15) 8 (53%) 7 (47%)
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